Hsa-miR-34a作为肾癌早期诊断指标的临床探讨
MCE 站:hsa-miR-34a-3p antagomir 产品活性:hsa-miR-34a-3p antagomir 是一种经过特殊化学修饰的成熟miRNA的互补单链,全链进行甲氧基修饰,在5'端和3'端分别有2个和4个硫代骨架修饰,并在3'端连接有高亲和性胆固醇修饰。miRNA antagomir通过特异性结合成熟miRNA,阻止miRNA与其靶基因的互补配对,从而抑制miRNA的功...
MiR-34a3-Methyl adenin (3MA)Poly L-lysin (PLL)AutophagyApoptosisCo-delivery of tumor suppressor microRNA and drugs attracted much attention for cancer therapy.A new modified cellulose dialdehyde (MDAC) nanocarrier responsive to lysosomal pH designedCo-loading of hsa-miR-34a polyplexes and 3-...
目的从人胶质瘤组织及正常脑组织中分离并定量hsa-mir-34a,及在mRNA和蛋白水 平检测p53、BCL-2等的表达。 方法用茎环RT-PCR(stem-loopRT-PCR)方法对人胶质瘤中hsa-mir-34a进行检测 和定量;用实时荧光定量RT-PCR对p53、BCL-2在mRNA水平的表达进行定量;用 ...
Conclusion: Hsa - miR - 34a may be involved in invasion in renal cell carcinoma, hsa - miR - 34a may be as a specific biomarker in renal cell carcinoma early diagnosis.%目的:探讨hsa-miR-34a作为肾癌早期诊断分子指标的可行性.方法:选择27例肾细胞癌患者的肿瘤组织及相匹配的正常组织进行高通量的...
hsa-miR-34a-5p targets RAF1, as the signaling factor of the MAPK pathway, and potentiates the temozolomide anti-tumoral effect on A172 cells.doi:10.17179/excli2023-6404Shadbad, Mahdi AbdoliBaghbanzadeh, AmirBaradaran, BehzadEXCLI Journal
利用PANTHER和DAVID在线工具对hsa-miR-34a的靶基因进行基因本体论(GO)富集分析和REACTOME信号通路富集分析.采用STRING数据库构建hsa-miR-34a的靶基因对应蛋白质的互作网络.结果hsa-miR-34a在乳腺癌,前列腺癌,膀胱癌等肿瘤中表达显著降低.编码hsa-miR-34a的基因序列在不同物种间具有高度保守性.共获得225个靶基因,采用...
Among them, hsa‐mir‐34a seems to be significantly upregulated, while hsa‐mir‐124 and hsa‐mir‐204 are significantly downregulated. The target genes of the signature miRNAs are mainly enriched in hsa04015:Rap1 signaling pathway, hsa04142:lysosome, and hsa04360:axon guidance, indicating that ...